Berlin, Germany – National Institutes of Health (NIH) Director Jay Bhattacharya assured lawmakers on Tuesday that the agency remains committed to fully obligating its $48.7 billion budget for fiscal year 2026, despite a significant slowdown in grant awards reported earlier this year. The pledge came during an oversight hearing before the House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, addressing concerns that unspent funds could be returned to the treasury.
The current pace of grant distribution has raised eyebrows within the scientific community. An analysis by researchers at Johns Hopkins University revealed that, roughly halfway through the fiscal year, the NIH has awarded approximately 74% fewer competitive, or new, awards compared to the average rate observed between 2021 and 2024. This substantial lag has prompted questions about the agency’s ability to effectively distribute funding and maintain momentum in critical research areas.
Dr. Bhattacharya, who assumed the role of NIH Director in April 2025, following his confirmation by the Senate on March 25, 2025, emphasized his commitment to responsible spending. He repeatedly stated during the hearing that the NIH will fully utilize its allocated budget before the end of the fiscal year. This assurance aims to alleviate anxieties among researchers and institutions reliant on NIH funding for their work.
Understanding the Grant Funding Slowdown
The reasons behind the slower grant award rate are multifaceted. Several factors are believed to be contributing to the issue, including a recent shift in NIH priorities, administrative challenges, and a backlog of applications. The NIH has been focusing on implementing new policies aimed at enhancing rigor and transparency in the grant review process, which may have inadvertently created bottlenecks. The agency is navigating a complex landscape of competing research demands and budgetary constraints.
The NIH’s budget for fiscal year 2026 represents a significant investment in biomedical research and public health. The $48.7 billion allocation, boosted by $415 million after rejecting proposed cuts from President Trump, supports a wide range of research initiatives, from cancer treatment and Alzheimer’s disease research to infectious disease preparedness and global health programs.
The slowdown in grant awards particularly impacts early-career researchers and those seeking funding for innovative, high-risk projects. Competitive grants are crucial for these individuals, providing the financial support needed to launch their careers and pursue groundbreaking research. A delay in funding can disrupt research timelines, hinder scientific progress, and potentially discourage talented individuals from entering the field.
Bhattacharya’s Background and Leadership
Jayanta Bhattacharya, a physician and health economist, brings a unique perspective to the leadership of the NIH. Born in Kolkata, India, in 1968, he earned his BA, MA, MD, and PhD from Stanford University. Prior to his appointment as NIH Director, Dr. Bhattacharya was a professor of medicine, economics, and health research policy at Stanford, where his research focused on the economics of healthcare and population aging. He is now an emeritus professor at Stanford.
Notably, Dr. Bhattacharya co-authored the Great Barrington Declaration in 2020, a controversial statement advocating for a more targeted approach to pandemic response, emphasizing the protection of vulnerable populations while allowing for greater societal openness. This stance positioned him as a vocal critic of widespread lockdowns and mask mandates during the COVID-19 pandemic. His appointment as NIH Director was met with both praise and criticism, reflecting the diverse perspectives surrounding his views on public health policy.
Currently, Dr. Bhattacharya is also serving as the acting director of the Centers for Disease Control and Prevention (CDC), a role he assumed on February 18, 2026, in addition to his duties at the NIH. This dual leadership position underscores the interconnectedness of these two critical public health agencies and the importance of coordinated efforts in addressing national health challenges.
Concerns and Potential Consequences
The prospect of returning unused funds to the treasury is a significant concern for the NIH and the broader scientific community. Such a scenario would not only represent a loss of valuable resources for research but could also lead to cuts in future funding allocations. The NIH operates on a budget cycle, and unused funds are often viewed as an indication of inefficiency or lack of require.
Several stakeholders have expressed their concerns to lawmakers. Research institutions, patient advocacy groups, and scientific societies have all urged the NIH to expedite the grant award process and ensure that funding reaches researchers in a timely manner. They emphasize the importance of sustained investment in biomedical research for advancing scientific knowledge, improving public health, and driving economic growth.
The Johns Hopkins analysis highlighted the severity of the slowdown, noting the substantial decrease in new awards. This data has fueled the debate over the NIH’s administrative efficiency and its ability to effectively manage its budget. Lawmakers on the House Appropriations Subcommittee pressed Dr. Bhattacharya for a detailed explanation of the challenges and a concrete plan to address them.
Addressing the Challenges and Moving Forward
Dr. Bhattacharya outlined several steps the NIH is taking to accelerate the grant award process. These include streamlining administrative procedures, increasing staffing levels in grant review offices, and implementing new technologies to improve efficiency. He also emphasized the importance of clear communication with researchers and institutions to provide guidance and support throughout the application process.
The NIH is also exploring ways to prioritize funding for critical research areas, such as cancer, Alzheimer’s disease, and emerging infectious diseases. This may involve reallocating resources from lower-priority projects or focusing on research that has the potential for rapid translation into clinical applications. The agency is committed to ensuring that its funding decisions align with national health priorities and address the most pressing public health challenges.
Dr. Bhattacharya acknowledged the need for greater transparency in the grant review process. He pledged to provide researchers with more detailed feedback on their applications and to ensure that the review process is fair and unbiased. This commitment to transparency aims to build trust and confidence among the scientific community.
The Role of the NIH in Biomedical Research
The National Institutes of Health is the primary federal agency responsible for conducting and supporting biomedical research. It comprises 27 institutes and centers, each focused on a specific area of health and disease. The NIH funds research at universities, hospitals, and research institutions across the United States and around the world.
The NIH’s research portfolio spans a wide range of disciplines, including genomics, proteomics, immunology, neuroscience, and behavioral science. Its discoveries have led to breakthroughs in the prevention, diagnosis, and treatment of countless diseases and conditions. The NIH plays a vital role in improving the health and well-being of millions of people worldwide.
Dr. Bhattacharya, as the 18th Director of the NIH, is responsible for overseeing the agency’s research activities, managing its budget, and providing leadership in the field of biomedical research. He is the first Indian American to lead the NIH, marking a significant milestone in the agency’s history.
The next key checkpoint will be the NIH’s report to the House Appropriations Subcommittee in June 2026, detailing progress on grant awards and budget utilization. Researchers and stakeholders will be closely monitoring this report to assess the agency’s efforts to address the current challenges and ensure the continued flow of funding for critical research initiatives. We encourage readers to share their perspectives and experiences with NIH funding in the comments below.
Related reading